The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease and the Risk of Hospitalization for Pneumonia
Abstract
RATIONALE: Inhaled corticosteroids are commonly prescribed to patients with chronic obstructive pulmonary disease (COPD). OBJECTIVES: To examine whether these medications might be associated with an excess risk of pneumonia. METHODS: We conducted a nested case-control study within a cohort of patients with COPD from Quebec, Canada, over the period 1988-2003, identified on the basis of administrative databases linking hospitalization and drug-dispensing information. Each subject hospitalized for pneumonia during follow-up (case subjects) was age and time matched to four control subjects. The effect of the use of inhaled corticosteroids was assessed by conditional logistic regression, after adjusting for comorbidity and COPD severity. MEASUREMENTS AND MAIN RESULTS: The cohort included 175,906 patients with COPD of whom 23,942 were hospitalized for pneumonia during follow-up, for a rate of 1.9 per 100 per year, and matched to 95,768 control subjects. The adjusted rate ratio of hospitalization for pneumonia associated with current use of inhaled corticosteroids was 1.70 (95% confidence interval [CI], 1.63-1.77) and 1.53 (95% CI, 1.30-1.80) for pneumonia hospitalization followed by death within 30 days. The rate ratio of hospitalization for pneumonia was greatest with the highest doses of inhaled corticosteroids, equivalent to fluticasone at 1,000 microg/day or more (rate ratio, 2.25; 95% CI, 2.07-2.44). All-cause mortality was similar for patients hospitalized for pneumonia, whether or not they had received inhaled corticosteroids in the recent past (7.4 and 8.2%, respectively). CONCLUSIONS: The use of inhaled corticosteroids is associated with an excess risk of pneumonia hospitalization and of pneumonia hospitalization followed by death within 30 days, among elderly patients with COPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
Guidelines for the diagnosis and management of asthma.
Solomon, P. A. (1992) · PubMed · Cited by 2,004
National Hospital Discharge Survey, 1988: Archival Version
United States Department of Health and Human Services. National Center for Health Statistics (1991) · ICPSR Data Holdings · doi:10.3886/icpsr09521 · Cited by 1,310
Pauwels, R. A., Löfdahl, C.-G., Laitinen, L. A., Schouten, J. P., Postma, D. S., Pride, N. B., & Ohlsson, S. V. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402503 · Cited by 1,074
Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Lipworth, B. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.9.941 · Cited by 918 · cited 1×
“High doses of ICS are known to be associated with systemic effects and 1,000 g of inhaled fluticasone, the most commonly used inhaled corticosteroid in Canada, is estimated to be equivalent to approximately 10 mg of prednisone per day when the systemic effect is evaluated by suppression of serum cortisol ( 25 ).”
BackgroundEffect of Systemic Glucocorticoids on Exacerbations of Chronic Obstructive Pulmonary Disease
Niewoehner, D. E., Erbland, M. L., Deupree, R. H., Collins, D., Gross, N. J., Light, R. W., Anderson, P., & Morgan, N. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906243402502 · Cited by 875
(2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432601 · Cited by 830
Vestbo, J., Søorensen, T., Lange, P., Brix, A., Torre, P., & Viskum, K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10019-3 · Cited by 816
Tamblyn, R., Lavoie, G., Petrella, L., & Monette, J. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)00234-h · Cited by 577
Cited by
Chronic obstructive pulmonary disease
Decramer, M., Janssens, W., & Miravitlles, M. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60968-9 · Cited by 972
Guidelines for the management of adult lower respiratory tract infections - Full version
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03672.x · Cited by 942
Suissa, S., Dell'Aniello, S., & Ernst, P. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201518 · Cited by 779
Self-citationO’Donnell, D. E., Aaron, S., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M., Ford, G., Gervais, A., Goldstein, R., Hodder, R., et al. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/830570 · Cited by 693
Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Pancholi, M., Venge, P., Lomas, D. A., Barer, M. R., Johnston, S. L., Pavord, I. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1553oc · Cited by 612
Guidelines for the management of adult lower respiratory tract infections - Summary
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03602.x · Cited by 468
Inhaled corticosteroids in COPD and the risk of serious pneumonia
Suissa, S., Patenaude, V., Lapi, F., & Ernst, P. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202872 · Cited by 444
Self-citationCrim, C., Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Willits, L. R., Yates, J. C., & Vestbo, J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00193908 · Cited by 432
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
Kew, K. M., & Seniukovich, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010115.pub2 · Cited by 398
Ferguson, G. T., Rabe, K. F., Martinez, F. J., Fabbri, L. M., Wang, C., Ichinose, M., Bourne, E., Ballal, S., Darken, P., DeAngelis, K., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30327-8 · Cited by 379
Drummond, M. B., Dasenbrook, E. C., Pitz, M. W., Murphy, D. J., & Fan, E. (2008) · JAMA · doi:10.1001/jama.2008.717 · Cited by 364
Singh, S., Amin, A. V., & Loke, Y. K. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.550 · Cited by 346
Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis
Andréjak, C., Nielsen, R., Thomsen, V. Ø., Duhaut, P., Sørensen, H. T., & Thomsen, R. W. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-201772 · Cited by 340
Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression
Suissa, S., Kezouh, A., & Ernst, P. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.06.019 · Cited by 317
Self-citationBusacker, A., Newell, J. D., Keefe, T., Hoffman, E. A., Granroth, J. C., Castro, M., Fain, S., & Wenzel, S. (2009) · Chest · doi:10.1378/chest.08-0049 · Cited by 287
Barnes, P. J. (2010) · Pharmaceuticals · doi:10.3390/ph3030514 · Cited by 277
Schultze, A., Walker, A. J., MacKenna, B., Morton, C. E., Bhaskaran, K., Brown, J. P., Rentsch, C. T., Williamson, E., Drysdale, H., Croker, R., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30415-x · Cited by 275
Nannini, L. J., Poole, P., Milan, S. J., Holmes, R., & Normansell, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003794.pub4 · Cited by 274
Risk Factors for Aspiration Pneumonia in Frail Older People: A Systematic Literature Review
van der Maarel-Wierink, C. D., Vanobbergen, J. N. O., Bronkhorst, E. M., Schols, J. M. G. A., & de Baat, C. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.12.099 · Cited by 262
Tay, H. L., Kaiko, G. E., Plank, M., Li, J., Maltby, S., Essilfie, A.-T., Jarnicki, A., Yang, M., Mattes, J., Hansbro, P. M., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004549 · Cited by 67
“In chronic lung disease, corticosteroid treatment can lead to immunosuppression and increase the risk of pneumonia [23].”
BackgroundThe use of inhaled corticosteroids and the risk of adrenal insufficiency
Lapi, F., Kezouh, A., Suissa, S., & Ernst, P. (2013) · European Respiratory Journal · doi:10.1183/09031936.00080912 · Cited by 63
Self-citationInhalational steroids and iatrogenic Cushing's syndrome
A.V, R. (2014) · The Open Respiratory Medicine Journal · doi:10.2174/1874306401408010074 · Cited by 17
“Use of ICS are associated with increased risk of pneumonia, tuberculosis, easy bruising, osteoporosis, diabetes, oro-pharyngeal candidiasis, hoarseness of voice and even iatrogenic CS in patients with COPD, where the risk-benefit ratio has to be considered before starting steroids [17-24].”
Background
Metadata
- Authors
- Ernst, P., Gonzalez, A. V., Brassard, P., & Suissa, S.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-07-15
- Volume
- 176
- Issue
- 2
- Pages
- 162-166
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2077672954
- Cited by
- 389
- References
- 24
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.